source
- ADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...Endpoints · 1mo ago↗ source
- STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.STAT · 1mo ago↗ source
- Male puberty is understudied — but when it starts may predict long-term health risksDue to a significant gender gap, far less is known about the health risks of early or late puberty onset among boys than girls.STAT